SANGAMO THERAPEUTICS INC (SGMO) Stock Price, Quote, News and Overview
NASDAQ:SGMO - Nasdaq - US8006771062 - Common Stock - Currency: USD
SGMO Quote, Performance and Key Statistics
1.04
+0.04 (+4%)
The current stock price of SGMO is 1.04 USD. In the past month the price decreased by -18.11%. In the past year, price increased by 14.78%.
SGMO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About SGMO
Company Profile
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Richmond California, California and currently employs 405 full-time employees. The company went IPO on 2000-04-06. The firm's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The firm's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.
Company Info
SANGAMO THERAPEUTICS INC
501 Canal Blvd.
Richmond California CALIFORNIA 94005 US
CEO: Alexander D. Macrae
Employees: 405
Company Website: https://www.sangamo.com/
Investor Relations: https://investor.sangamo.com
Phone: 15109706000
SANGAMO THERAPEUTICS INC / SGMO FAQ
What is the stock price of SANGAMO THERAPEUTICS INC today?
The current stock price of SGMO is 1.04 USD. The price increased by 4% in the last trading session.
What is the ticker symbol for SANGAMO THERAPEUTICS INC stock?
The exchange symbol of SANGAMO THERAPEUTICS INC is SGMO and it is listed on the Nasdaq exchange.
On which exchange is SGMO stock listed?
SGMO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SANGAMO THERAPEUTICS INC stock?
14 analysts have analysed SGMO and the average price target is 5.27 USD. This implies a price increase of 406.73% is expected in the next year compared to the current price of 1.04. Check the SANGAMO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SANGAMO THERAPEUTICS INC worth?
SANGAMO THERAPEUTICS INC (SGMO) has a market capitalization of 217.00M USD. This makes SGMO a Micro Cap stock.
How many employees does SANGAMO THERAPEUTICS INC have?
SANGAMO THERAPEUTICS INC (SGMO) currently has 405 employees.
What are the support and resistance levels for SANGAMO THERAPEUTICS INC (SGMO) stock?
SANGAMO THERAPEUTICS INC (SGMO) has a support level at 1.01 and a resistance level at 1.05. Check the full technical report for a detailed analysis of SGMO support and resistance levels.
Is SANGAMO THERAPEUTICS INC (SGMO) expected to grow?
The Revenue of SANGAMO THERAPEUTICS INC (SGMO) is expected to decline by -66.94% in the next year. Check the estimates tab for more information on the SGMO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SANGAMO THERAPEUTICS INC (SGMO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SGMO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SGMO, evaluating the profitability, health, valuation and growth aspects
- SANGAMO THERAPEUTICS INC (SGMO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SANGAMO THERAPEUTICS INC (SGMO) Sales and EPS estimates to see what analysts future expectations are.
- SANGAMO THERAPEUTICS INC (SGMO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SANGAMO THERAPEUTICS INC (SGMO) Insider and Institutional Ownership to learn about the owners and their transactions.
- SANGAMO THERAPEUTICS INC (SGMO) Stock Chart to make your own analysis
- SANGAMO THERAPEUTICS INC (SGMO) Latest news and press-releases to stay up to date.
Does SANGAMO THERAPEUTICS INC (SGMO) stock pay dividends?
SGMO does not pay a dividend.
When does SANGAMO THERAPEUTICS INC (SGMO) report earnings?
SANGAMO THERAPEUTICS INC (SGMO) will report earnings on 2025-03-17, after the market close.
What is the Price/Earnings (PE) ratio of SANGAMO THERAPEUTICS INC (SGMO)?
SANGAMO THERAPEUTICS INC (SGMO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.75).
What is the Short Interest ratio of SANGAMO THERAPEUTICS INC (SGMO) stock?
The outstanding short interest for SANGAMO THERAPEUTICS INC (SGMO) is 12.54% of its float. Check the ownership tab for more information on the SGMO short interest.
SGMO Technical Analysis
SGMO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SGMO. SGMO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SGMO Financial Highlights
Over the last trailing twelve months SGMO reported a non-GAAP Earnings per Share(EPS) of -0.75. The EPS increased by 48.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -165.31% | ||
| ROE | -470% | ||
| Debt/Equity | 0 |
SGMO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 79% to SGMO. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 67.56% and a revenue growth -66.94% for SGMO